News
As drug development programs advance toward and proceed into clinical studies, they often expand across multiple sample collection sites. This accelerates enrollment, building a far larger data set than a single early operation site could achieve in a reasonable time.
However, collection at multiple sites introduces wider degrees of variability both for known sources of error and new types of uncertainty. For example: a larger patient population introduces wider background variabilities; different sample collection sites introduce new personnel and sample handling tendencies.
Bioanalytical method development starts with controlled settings to minimize variability from aliquot preparation and instrumentation. Nonideal samples should then be introduced to proceed from method development into method validation. But the leap from preclinical to multisite clinical trials introduces more preanalytical variability, including sample collection, processing, storage, and transport, involving sites and personnel who were never part of the more controlled preclinical process.
Appropriate grappling with preanalytical sources of variability can make the difference between a clinical trial leading to a new drug approval (NDA) and simply being evidence that more work is needed. Put another way, even seemingly minor differences in how biospecimens are handled across sites can influence analyte stability, impacting pharmacokinetic (PK) data and the confidence sponsors place in study results.
By accounting for these variables during bioanalytical method development and validation, sponsors can establish standardized sample handling procedures that support reliable PK/TK data generation as programs progress into multisite clinical development.
Preanalytical variability refers to differences introduced before bioanalysis begins, i.e., due to sample collection, handling, or sample transportation. Once a biological sample is collected, every subsequent step has the potential to affect analyte integrity if not carefully controlled. Minimizing this variability through standard operating procedures (SOPs) better ensures that downstream bioanalytical data interpretation makes for defensible regulatory filings.
Common preanalytical variables that can influence bioanalytical results include:
While each factor may appear minor in isolation, the cumulative effect across dozens to hundreds of clinical sites and many thousands of samples can introduce unnecessary variability into PK datasets.
For sponsors evaluating drug exposure, dose proportionality, or exposure-response relationships, distinguishing true biomedical differences from sample treatment variability introduced during biospecimen handling becomes essential.
Early nonclinical studies or small clinical investigations often involve relatively few collection sites operating under closely monitored conditions. As programs expand into larger multisite studies, maintaining consistency becomes more complex.
Individual clinical sites may have different staffing models, laboratory workflows, equipment, shipping schedules, and operational constraints. Additional factors based on geography, transportation infrastructure, and international shipping barriers can further add variability that influences sample quality. Even when sites follow the same protocol, differences in processing timelines or storage practices may influence sample quality.
For example, one site may process plasma immediately after collection, while another experiences routine delays before centrifugation. Samples shipped over weekends may encounter longer transit times than those shipped earlier in the week. Environmental conditions during transport can also vary depending on geographic location and shipping logistics.
These operational differences do not necessarily indicate protocol deviations, but they can contribute to greater variability if SOPs to dictate acceptable handling parameters have not been clearly established.
The most controllable, and thus effective, time to address sample handling variability is before large-scale clinical studies begin. The earlier that the bioanalytical lab is involved in this process, so samples arrive within tolerable parameters, all the better for generating and defensibly interpreting the data.
During bioanalytical method development and validation, analytical scientists can evaluate how expected collection and handling conditions affect analyte stability. Rather than assuming ideal laboratory conditions, stability assessments help define the acceptable operating ranges that future clinical sites can consistently follow.
These evaluations may include:
The resulting data establish scientifically supported collection and handling requirements that can be incorporated into study manuals, laboratory procedures, and site-specific training materials. That is, insert SOPs into every context that might contribute to sample variability to minimize uncertainty that challenges defensible bioanalytical data interpretation.
This proactive approach helps ensure that differences observed in PK data and other relevant measurements reflect true biological variability rather than inconsistencies in specimen handling.
Bioanalytical contract research organizations (CROs) with integrated method development and method validation mastery can inform these parameters early, allowing sample handling requirements to be aligned with validated assay performance before clinical studies expand. Further, bioanalytical CROs that also have in-house PK/TK departments go that much further to set up for INDs that are more ready to scale up to phased clinical trials.
Suggested Internal Links:
Devising and deploying SOPs does not eliminate every source of variability in clinical research, but it significantly reduces avoidable sources that can complicate data interpretation.
Well-defined collection procedures help ensure that samples arriving from different clinical sites have been handled under comparable conditions. This supports more reproducible bioanalytical measurements and strengthens confidence in downstream assessment. For example, establishing sample handling SOPs early means PK/TK analyses more reliably inform IND filings, study design, and trial execution.
Reliable sample handling practices also benefit study teams by:
As drug development programs become increasingly global and decentralized, sample handling SOPs become an important component of overall data quality and thus reliability.
Managing sample handling variability extends beyond developing laboratory procedures. It requires understanding how collection practices, analyte stability, bioanalytical methods, and PK/TK modeling need to work together throughout drug development.
An integrated bioanalytical partner can help sponsors evaluate potential risks during method development, inform appropriate handling parameters to ensure proper method validation, and generate bioanalytical data using standardized workflows informed by validation studies.
Addressing variability after it appears in study data is far too late. Not only might a failure to control for sample collection variability complicate data interpretation but it might necessitate revalidation or even completely new method development. Such delays can derail even the most promising candidates, meaning patients might never benefit from the years of dedicated biomedical research. CROs that integrate method development, method validation, bioanalytical sample analysis, and PK/TK modeling within a single laboratory environment can provide greater continuity across the bioanalytical workflow, supporting reproducible data generation from early development through IND and onto clinical studies.
Suggested Internal Links:
As clinical programs expand across multiple sites, controlling pre-analytical variability becomes increasingly important for maintaining data quality.
While sophisticated analytical methods remain essential, reliable bioanalysis begins long before considering instrumentation parameters for LC-MS/MS analysis. Establishing scientifically supported sample collection, handling, storage, and transportation parameters during method development and validation helps ensure that specimens arrive in conditions suitable for accurate quantitative analysis.
By addressing these variables early, sponsors can reduce unnecessary variability, strengthen confidence in PK/TK data, and support more informed development decisions throughout the clinical lifecycle.
When bioanalytical strategy, method development, validation, and PK/TK data generation are integrated within a single scientific partner, programs are better positioned to generate reproducible, regulatory-ready data that supports efficient drug development and sees promising therapies improve patients’ lives.
Disclaimer: This article is intended for educational and informational purposes and reflects the perspectives and expertise of the Alturas Analytics team. It is not a peer-reviewed scientific publication. Readers seeking additional scientific context are encouraged to review the supporting resources that may be referenced within this posting.
